FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment with Vargatef is not recommended in patients with moderate or severe hepatic impairment (see section 4.2).
Estonian: Mõõduka või raske maksapuudulikkusega patsientidel ei ole ravi Vargatefiga soovitatav (vt lõik 4.2).
English: What Vargatef looks like and contents of the pack Vargatef 100 mg soft capsules (capsules) are peach-coloured, opaque, oblong capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “100”.
Estonian: Vargatef 100mg pehmekapslid (kapslid) on piklikud läbipaistmatud virsikuvärvi kapslid, mille ühele küljele on musta tindiga trükitud ettevõtte Boehringer Ingelheimi sümbol ja “100”.
English: In case of bleeding, dose adjustment, interruption or discontinuation should be considered based on clinical judgement (see section 4.2).
Estonian: Verejooksu korral tuleb kliinilise hinnangu kohaselt kaaluda Vargatefi ravi katkestamist, annuse vähendamist või ravi ärajätmist (vt lõik 4.2).
English: Package leaflet: Information for the patient Vargatef 100 mg soft capsules nintedanib
Estonian: Pakendi infoleht: teave patsiendile Vargatef 100 mg pehmekapslid nintedaniib
English: Vargatef should be discontinued in patients with life-threatening venous thromboembolic reactions.
Estonian: Eluohtliku venoosse trombemboolia korral tuleb ravi Vargatefiga katkestada.
English: Package leaflet: Information for the patient Vargatef 150 mg soft capsules nintedanib
Estonian: Pakendi infoleht: teave patsiendile Vargatef 150 mg pehmekapslid nintedaniib
English: Each soft capsule contains100 mg nintedanib (as esilate).
Estonian: Üks pehmekapsel sisaldab 100mg nintedaniibi (esilaadina).
English: The safety, efficacy and pharmacokinetics of nintedanib have not been investigated in patients with severe hepatic impairment (Child Pugh C).
Estonian: Raske maksapuudulikkusega patsientidel (Child-Pugh staadium C) ei ole nintedaniibi ohutust, efektiivsust ja farmakokineetikat uuritud.
English: Interruption, dose reduction or discontinuation of therapy with Vargatef may be required (see section 4.2).
Estonian: Vajalik võib olla Vargatefi ravi katkestamine, annuse vähendamine või ravi ärajätmine (vt lõik 4.2).
English: MARKETING AUTHORISATION NUMBER(S) EU/1/14/954/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/14/954/001
English: The efficacy of nintedanib has not been investigated in patients with moderate hepatic impairment (Child Pugh B).
Estonian: Mõõduka maksapuudulikkusega patsientidel (Child-Pugh staadium B) ei ole nintedaniibi efektiivsust uuritud.
English: AUCτ,ss increased by 25 % for a 50 kg patient (5
Estonian: Võrreldes 71,5 kg mediaankehakaaluga patsiendiga oli AUCτ,ss 50 kg patsiendil (5. protsentiil) 25% suurem ja 100 kg patsiendil (95. porotsentiil) 19% väiksem.
English: Peach-coloured, opaque, oblong soft-gelatin capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and “100”.
Estonian: Läbipaistmatud virsikuvärvi piklikud želatiinist pehmekapslid, mille ühele küljele on musta tindiga trükitud ettevõtte Boehringer Ingelheimi sümbol ja “100”.
English: Dehydration, Weight decreased
Estonian: Vedelikupuudus, kehakaalu langus
English: Plasma levels of electrolytes should be monitored, if relevant gastrointestinal adverse events occur.
Estonian: Seisundite korral, mis võivad põhjustada seedetrakti kõrvaltoimeid, tuleb jälgida plasma elektrolüüdisisaldust.
English: Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with Vargatef (see section 4.2).
Estonian: Kõrvaltoimete raviks võib olla vajalik Vargatef-ravi katkestamine, annuse vähendamine või ravi ärajätmine (vt lõik 4.2).
English: Brown-coloured, opaque, oblong soft-gelatin capsule imprinted on one side in black with the Boehringer Ingelheim company symbol and “150”.
Estonian: Läbipaistmatud pruunid piklikud želatiinist pehmekapslid, mille ühele küljele on musta tindiga trükitud ettevõtte Boehringer Ingelheimi sümbol ja “150”.
English: NAME OF THE MEDICINAL PRODUCT Vargatef 150 mg capsules Nintedanib
Estonian: RAVIMPREPARAADI NIMETUS Vargatef 150 mg kapslid nintedanibum
English: Haemorrhage
Estonian: Ajumetastaasid
English: NAME OF THE MEDICINAL PRODUCT Vargatef 100 mg capsules Nintedanib
Estonian: RAVIMPREPARAADI NIMETUS Vargatef 100 mg kapslid nintedanibum
English: Stratified by baseline ECOG PS (0 versus 1), brain metastases at baseline (yes versus no) and prior treatment with bevacizumab (yes versus no).
Estonian: Stratifitseeritud ECOG funktsionaalse klassi algväärtuse (0 vs 1), uuringu alguse ajumetastaaside olemasolu (jah vs ei) ja eelneva bevatsisumaabiga ravi järgi (jah vs ei).
English: Each soft capsule contains150mg nintedanib (as esilate).
Estonian: Üks pehmekapsel sisaldab 150 mg nintedaniibi (esilaadina).
English: Shellac, iron oxide black (E172),propylene glycol (E1520)
Estonian: šellak, must raudoksiid (E172), propüleenglükool (E1520) Kuidas Vargatef välja näebja pakendi sisu
English: Stratified Log-Rank Test p-value** Disease control [%] Odds ratio (95 % CI) p-value+
Estonian: Stratifitseeritud Manteli-Coxi testi p-väärtus Haiguse ohje [%]
English: Fertility
Estonian: Veritsus
English: Iron oxide red (E172) Iron oxide yellow (E172)
Estonian: Kapsli kest želatiin glütserool (85%) titaandioksiid (E171) punane raudoksiid (E172) kollane raudoksiid (E172)
English: Pain in the stomach (abdomen)
Estonian: Valu kõhus
English: Alanine aminotransferase (ALT) increased,
Estonian: Alaniini aminotransferaasi (ALAT) tõus, aspartaadi aminotransferaasi (ASAT) tõus, aluselise fosfataasi väärtuse (ALP) suurenemine veres
English: NAME OF THE MEDICINAL PRODUCT Vargatef 100 mg soft capsules nintedanib
Estonian: RAVIMPREPARAADI NIMETUS Vargatef 100 mg pehmekapslid nintedanibum
English: Post-marketing bleeding events include but are not limited to gastrointestinal, respiratory and central nervous system organs, with the most frequent being respiratory (see also section 4.4).
Estonian: Kõige sagedamini esines verejookse respiratoorse süsteemi elundites (vt ka lõik 4.4).
English: Therapy with Vargatef should be permanently discontinued in patients who develop gastrointestinal perforation.
Estonian: Patsientidel, kellel tekib seedetrakti perforatsioon, tuleb ravi Vargatefiga püsivalt katkestada.
English: NAME OF THE MEDICINAL PRODUCT Vargatef 150 mg soft capsules nintedanib
Estonian: RAVIMPREPARAADI NIMETUS Vargatef 150 mg pehmekapslid nintedanibum
English: Shellac, iron oxide black (E172), propylene glycol (E1520)
Estonian: Šellak, must raudoksiid (E172), propüleenglükool (E1520) Kuidas Vargatef välja näeb ja pakendi sisu
English: Weight loss
Estonian: Maksapuudulikkus
English: Capsule shell Gelatin
Estonian: Kapsli kest:
English: Gastrointestinal perforations
Estonian: Seedetrakti perforatsioonid
English: Nausea ≥ grade 3 despite anti-emetic treatment Other non-haematological or haematological adverse reaction of ≥ grade 3
Estonian: ≥ 2. astme oksendamine JA/VÕI ≥ 3. astme iiveldus vaatamata antiemeetilisele ravile
English: Treatment interruption should be considered in patients who develop signs or symptoms of acute myocardial ischaemia.
Estonian: Ägeda müokardiisheemia tunnuste või sümptomitega patsientidel tuleb kaaluda ravi katkestamist.
English: Electrolyte imbalance
Estonian: Elektrolüüditasakaalu häire
English: The following is a list of main benefits shown in these studies:
Estonian: Alljärgnev on nende uuringute peamise kasulikkuse loetelu.
English: The full EPAR for Velcade can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Velcade kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: A risk management plan has been developed to ensure that Velcade is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Velcade võimalikult ohutu kasutamine.
English: What measures are being taken to ensure the safe and effective use of Velcade?
Estonian: Mis meetmed võetakse, et tagada Velcade ohutu ja efektiivne kasutamine?
English: Velcade must not be given by other routes.
Estonian: Velcadet ei tohi manustada teistel viisidel.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Velcade on 26 April 2004.
Estonian: Euroopa Komisjon andis Velcade müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 26. aprillil
English: As the company had supplied the additional information requested, the ‘exceptional circumstances' ended on 19 March 2012.
Estonian: Et ettevõte esitas vajaliku lisateabe, tühistati müügiloa erandkorras väljastatus 19. märtsil 2012.
English: If a patient develops severe side effects after a treatment cycle, the treatment must be suspended, delayed or the dose adjusted.
Estonian: Kui patsiendil tekivad pärast ravikuuri rasked kõrvalnähud, tuleb ravi peatada, edasi lükata või annust kohandada.
English: When Velcade is used with other medicines the restrictions for those medicines must also be taken into account, including the requirements for pregnancy testing and prevention with thalidomide.
Estonian: Kui Velcadet kasutatakse koos muude ravimitega, tuleb võtta arvesse ka nende ravimite piiranguid, sh raseduse testimise ja ennetamise nõuet talidomiidi korral.
English: Velcade bortezomib
Estonian: Velcade bortesomiib
English: The CHMP decided that Velcade's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Velcade kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: In addition, the company that markets Velcade will ensure that healthcare professionals receive educational material explaining how to calculate the dose and how to prepare and administer the medicine.
Estonian: Lisaks annab Velcadet turustaja tervishoiutöötajatele teabematerjalid, milles selgitatakse, kuidas arvutada annust ning valmistada ette ja manustada ravimit.
English: Velcade was originally authorised under ‘exceptional circumstances', because, for scientific reasons, limited information was available at the time of approval.
Estonian: Velcade müügiluba anti esialgu erandkorras, sest teaduslikel põhjustel ei olnud ravimi heakskiitmise ajal olemas selle kohta piisavat teavet.
English: The recommended starting dose is 1.3 mg per square metre body surface area (calculated using the patient's height and weight).
Estonian: Soovitatav algannus on 1,3 mg kehapindala ruutmeetri kohta (arvutatakse patsiendi pikkuse ja kaalu põhjal).
English: Other information about Velcade:
Estonian: Muu teave Velcade kohta
English: This document is a summary of the European public assessment report (EPAR) for Velcade.
Estonian: See on ravimi Velcade Euroopa avaliku hindamisaruande kokkuvõte.
English: When the proteins in the cancer cells, such as the proteins that control the growth of the cells, are not broken down, the cells are affected and they eventually die.
Estonian: Kui vähirakkudes sisalduvad valgud, näiteks raku kasvu reguleerivad valgud, ei lagune, kahjustab see rakke ja lõpuks need hävivad.
English: At least 72 hours must pass between two consecutive doses of Velcade.
Estonian: Velcade kahe annuse manustamise vaheline aeg peab olema vähemalt 72 tundi.
English: For more information about treatment with Velcade, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Velcadega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: • Around 34% of the patients responded partially or completely to treatment with Velcade (in a study in which Velcade was not compared with any other medicine)
Estonian: • Velcadega ravimisel tekkis ligikaudu 34%-l patsientidest osaline või täielik ravivastus (uuringus, kus Velcadet ei võrreldud ühegi muu ravimiga).
English: In multiple myeloma, Velcade has been evaluated in 10 main studies involving over 4,339 adults, which evaluated the benefits of Velcade alone or in combination with other treatments.
Estonian: Hulgimüeloomi ravis uuriti Velcadet 10 põhiuuringus, kus osales 4339 täiskasvanut ja kus hinnati Velcade kasulikkust ainuravimina või kombinatsioonis muude ravimitega.
English: It blocks the proteasome, which is a system within the cells that breaks down proteins when they are no longer needed.
Estonian: Toimeaine blokeerib proteasoome ehk aineid, mis lagundavad valke, mida rakud enam ei vaja.
English: Studies in multiple myeloma showed Velcade and combinations containing Velcade to be beneficial in several patient groups.
Estonian: Hulgimüeloomi uuringutes tõestati, et Velcade ja Velcadet sisaldavad kombinatsioonid on kasulikud mitmele patsiendirühmale.
English: The main measure of effectiveness was how long the patients lived without their disease getting worse.
Estonian: Efektiivsuse põhinäitaja oli progresseerumiseta elulemus (aeg, kui kaua patsiendid elasid haiguse süvenemiseta).
English: • adults whose disease is getting worse after at least one other treatment and who have already had, or cannot undergo, a blood stem-cell transplant.
Estonian: • Täiskasvanud, kelle haigus süveneb pärast vähemalt üht muud raviskeemi ja kellele on vereloome tüvirakke juba siiratud või seda ei saa teha.
English: The most serious adverse reactions include heart failure, tumour lysis syndrome (complications due to breakdown of cancer cells), pulmonary hypertension (high blood pressure in the arteries of the lungs), posterior reversible encephalopathy syndrome (a reversible brain disorder), acute diffuse infiltrative pulmonary disease (a severe lung problem), and autonomic neuropathy (damage to nerves controlling organs such as the bladder, eyes, gut, heart and blood vessels).
Estonian: Kõige raskemad kõrvalnähud on südamepuudulikkus, tuumori lüüsi sündroom (vähirakkude lagunemisest põhjustatud tüsistus), pulmonaarne hüpertensioon (kopsuarterite kõrgvererõhk), pöörduv posterioorne entsefalopaatia sündroom (teatud pöörduv ajuturse), äge difuusne infiltreeriv kopsuhaigus (teatud raske kopsuhaigus) ja autonoomne neuropaatia (kusepõie-, silma-, soole-, südame- ja veresoonte närvide kahjustus).
English: Velcade 1 mg must only be given by injection into a vein, while Velcade 3.5 mg is only given either by injection into a vein or under the skin.
Estonian: Velcadet annuses 1 mg tohib süstida ainult veeni, Velcadet annuses 3,5 mg tohib süstida kas ainult veeni või naha alla.
English: The active substance in Velcade, bortezomib, is a proteasome inhibitor.
Estonian: Velcade toimeaine bortesomiib on proteasoomi inhibiitor.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Velcade.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Velcade, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Velcade omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: What is Velcade?
Estonian: Mis on Velcade?
English: Why has Velcade been approved?
Estonian: Miks Velcade heaks kiideti?
English: For the full list of all side effects reported with Velcade, see the package leaflet.
Estonian: Velcade kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: In mantle cell lymphoma, Velcade was evaluated in a main study involving 487 previously untreated adults who were not considered suitable for blood stem-cell transplantation.
Estonian: Mantelrakulise lümfoomi ravis uuriti Velcadet põhiuuringus, kus osales 487 varem ravimata täiskasvanut, kellele ei saanud siirata vereloome tüvirakke.
English: Velcade must not be used in people who are hypersensitive (allergic) to bortezomib, boron or to any of the other ingredients.
Estonian: Velcadet ei tohi kasutada patsiendid, kes on bortesomiibi, boori või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Velcade is a cancer medicine that contains the active substance bortezomib.
Estonian: Velcade on vähiravim, mis sisaldab toimeainena bortesomiibi.
English: Doses of Velcade are given intermittently, with rest periods in between doses, in treatment cycles of three to six weeks depending on whether Velcade is given alone or in combination with other medicines.
Estonian: Velcadet manustatakse järk-järgult, jättes annuste vahele puhkeperioodi, nii et ravikuurid kestavad 36 nädalat sõltuvalt sellest, kas Velcadet kasutatakse ainuravimina või koos muude ravimitega.
English: The most commonly reported side effects during treatment with Velcade are nausea (feeling sick), diarrhoea, constipation, vomiting, fatigue (tiredness), pyrexia (fever), thrombocytopenia (low blood platelets count), anaemia (low red blood cell counts), neutropenia (low levels of neutrophils, a type of white blood cell that fights infection), peripheral neuropathy (nerve damage in the hands and feet), headache, paraesthesia (unusual sensations like pins and needles), decreased appetite, dyspnoea (difficulty breathing), rash, herpes zoster (shingles) and myalgia (muscle pain).
Estonian: Kõige sagedamini teatatud Velcade ravi kõrvalnähud on iiveldus, kõhulahtisus, kõhukinnisus, oksendamine, väsimus, püreksia (palavik), trombotsütopeenia (trombotsüütide vähesus), aneemia (erütrotsüütide vähesus), neutropeenia (neutrofiilide vähesus), perifeerne neuropaatia (käte ja jalgade närvikahjustused), peavalu, paresteesia (vääraistingud, nt nahanõelatunne), isutus, düspnoe (raskendatud hingamine), lööve, vöötohatis ja lihasvalu.
English: It must not be given to patients with acute diffuse infiltrative pulmonary disease or pericardial disease (disease affecting the sac that surrounds the heart).
Estonian: Ravimit ei tohi kasutada patsiendid, kellel on äge difuusne infiltreeruv kopsuhaigus (teatud raske kopsuhaigus) või südamepauna haigus.
English: What is the risk associated with Velcade?
Estonian: Mis riskid Velcadega kaasnevad?
English: • patients given Velcade with pegylated liposomal doxorubicin whose disease was getting worse after having failed to respond to at least one other treatment, lived for 9.3 months without their disease getting worse compared to 6.5 months for patients receiving Velcade alone.
Estonian: • Velcadet koos pegüleeritud liposomaalse doksorubitsiiniga saanud patsientidel, kelle haigus süvenes pärast seda, kui neil ei tekkinud ravivastust vähemalt ühele muule ravile, oli progresseerumiseta elulemus 9,3 kuud ja Velcadet ainuravimina kasutanud patsientidel 6,5 kuud.
English: The main measures of effectiveness in these studies were the number of patients who responded to treatment and how long the patients lived without their disease getting worse.
Estonian: Efektiivsuse põhinäitaja oli ravivastusega patsientide arv ja aeg haiguse süvenemiseni.Efektiivsuse põhinäitaja oli nendes uuringutes ravivastusega patsientide arv ja aeg haiguse süvenemiseni.
English: • previously untreated patients who are going to receive high-dose chemotherapy followed by a blood stem-cell transplant.
Estonian: • Varem ravimata patsiendid, kellele hakatakse tegema suure annusega keemiaravi, millele järgneb vereloome tüvirakkude siirdamine.
English: Velcade is used to treat multiple myeloma, a blood cancer, in the following groups of patients:
Estonian: Velcadet kasutatakse hulgimüeloomi (teatud verevähk) raviks järgmistel patsiendirühmadel.
English: Treatment with Velcade should only be started and given under the supervision of a doctor who has experience in the use of cancer chemotherapy.
Estonian: Ravi Velcadega tohib alustada üksnes vähi keemiaravis kogenud arst ning ravi peab toimuma tema järelevalve all.
English: • Among patients with worsening disease that had come back or failed to respond to at least one other treatment, around 70% responded to treatment with the Velcade-dexamethasone combination.
Estonian: • Nende süveneva haigusega patsientide hulgas, kelle haigus oli taastunud või kellel ei tekkinud ravivastust vähemalt ühele muule raviviisile, tekkis Velcade ja deksametasooni kombinatsioonile ravivastus ligikaudu 70%-l patsientidest.
English: Velcade is also used to treat mantle cell lymphoma, another blood cancer, in untreated adults who cannot have blood stem-cell transplantation.
Estonian: Velcadet kasutatakse ka teist tüüpi verevähi, mantelrakulise lümfoomi raviks varem ravimata täiskasvanutel, kellele ei saa siirata vereloome tüvirakke.
English: In these patients, Velcade is used in combination with melphalan and prednisone;
Estonian: Velcadet kasutatakse neil patsientidel koos melfalaani ja prednisooniga.
English: • previously untreated adults who cannot have high-dose chemotherapy with a blood stem-cell transplant.
Estonian: • Varem ravimata täiskasvanud, kellel ei saa kasutada suure annusega keemiaravi koos vereloome tüvirakkude siirdamisega.
English: In addition, 49% of these patients responded to Velcade plus thalidomide and dexamethasone, compared with about 26% who responded to treatment containing Velcade plus other anticancer drugs, and 17% who responded to thalidomide and dexamethasone alone.
Estonian: Nendest patsientidest tekkis ravivastus ka Velcade, talidomiidi ja deksametasooni kombinatsioonile 49%-l patsientidest, samas oli patsiente, kellel tekkis ravivastus Velcade ja muude vähiravimite kombinatsioonile, ligikaudu 26%, ja patsiente, kellel tekkis ravivastus ainuravimitena kasutatavatele talodomiidile ja deksametasoonile, 17%.
English: • The study that compared Velcade given under the skin with Velcade given into a vein showed that the percentage of patients who responded partially or completely to treatment was the same (42%) when using either route of administration.
Estonian: • Uuringus, kus võrreldi naha alla süstitava Velcade toimet veeni süstitava Velcade toimega, ilmnes, et olenemata manustamisviisist oli ravile osaliselt või täielikult vastanud patsientide protsent sama
English: In mantle cell lymphoma, patients treated with a combination of Velcade plus rituximab, cyclophosphamide, doxorubicin and prednisone lived longer without their disease getting worse (24.7 months) than those given the same combination but with vincristine in place of Velcade (14.4 months).
Estonian: Mantelrakulise lümfoomi ravis oli progresseerumiseta elulemus pikem (24,7 kuud) patsientidel, keda raviti Velcade ja rituksimabi, tsüklofosfamiidi, doksorubitsiini ja prednisooni kombinatsiooniga, kui nendel, kes võtsid sama kombinatsiooni, kuid kellel Velcade oli asendatud vinkristiiniga (14,4 kuud).
English: In this study, Velcade together with rituximab, cyclophosphamide, doxorubicin and prednisone was compared with the same combination containing another medicine, vincristine, in place of Velcade.
Estonian: Selles uuringus võrreldi Velcade ja rituksimaabi, tsüklofosfamiidi, doksorubitsiini ja prednisooni kombinatsiooni sarnase kombinatsiooniga, kus Velcade asemel kasutati vinkristiini.
English: For mantle cell lymphoma, Velcade is used in combination with rituximab, cyclophosphamide, doxorubicin and prednisone.
Estonian: Mantelrakulise lümfoomi ravis kasutatakse Velcadet kombineerituna rituksimabi, tsüklofosfamiidi, doksorubitsiini ja prednisooniga.
English: • Around 15% of patients who were candidates for high-dose chemotherapy and a blood stem-cell transplant responded to treatment with Velcade plus dexamethasone, compared with 6% of those given standard combinations.
Estonian: • Patsientidest, kellele kavatseti teha suure annusega keemiaravi koos vereloome tüvirakkude siirdamisega, tekkis ravivastus Velcade ja deksametasooni kombinatsiooni uuringurühmas ligikaudu 15%-l ja ravimite tavakombinatsiooni uuringurühmas 6%-l patsientidest.